# Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

> **NCT05009082** · PHASE3 · RECRUITING · sponsor: **AGO Study Group** · enrollment: 970 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05009082
- **Lead sponsor:** AGO Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2028-12
- **Final completion:** 2031-12
- **Target enrollment:** 970 (ESTIMATED)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009082, "Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05009082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*